Northwest Capital Management Inc raised its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 42.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,664 shares of the company’s stock after acquiring an additional 495 shares during the quarter. Northwest Capital Management Inc’s holdings in Johnson & Johnson were worth $258,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. LCM Capital Management Inc lifted its holdings in shares of Johnson & Johnson by 0.7% in the fourth quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after buying an additional 61 shares in the last quarter. Arbor Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.3% in the fourth quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after buying an additional 61 shares in the last quarter. Sierra Capital LLC lifted its holdings in shares of Johnson & Johnson by 0.6% in the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock worth $1,773,000 after buying an additional 61 shares in the last quarter. MTM Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 0.5% in the first quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after buying an additional 61 shares in the last quarter. Finally, Lockerman Financial Group Inc. lifted its holdings in shares of Johnson & Johnson by 2.4% in the fourth quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock worth $474,000 after buying an additional 62 shares in the last quarter. 67.57% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock valued at $7,928,856 in the last 90 days. 0.20% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. The company had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. During the same period last year, the firm posted $2.59 EPS. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. On average, analysts anticipate that Johnson & Johnson will post 10.76 EPS for the current year.
Johnson & Johnson Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.80%. Johnson & Johnson’s payout ratio is 96.36%.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Raymond James boosted their target price on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a report on Monday, July 24th. StockNews.com began coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They issued a “strong-buy” rating on the stock. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Credit Suisse Group increased their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday. Eight equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $171.60.
Check Out Our Latest Stock Report on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- With Risk Tolerance, One Size Does Not Fit All
- 5 Best Office REITs to Buy Now
- What Investors Need to Know to Beat the Market
- Camping World Slashes its Dividend but Should You Cut the Stock?
- How to Invest in Social Media
- SoFi Downgraded: Here’s How To Still Make Money
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
